Lapatinib, 100 mg

STEMCELL Technologies supplies this small molecule research compound as a crystalline solid with a stated purity of ≥ 98%. It is a selective dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR, ErbB1) and human epidermal growth factor receptor 2 (HER2, ErbB2), each with an IC₅₀ of about 10 nM. The compound binds reversibly to the ATP binding pocket in an inactive-like conformation, preventing autophosphorylation, with reported Ki values of 3 nM and 13 nM for EGFR and HER2, respectively. Alternative names include GW572016, GSK 572016, GW2016, and Tyverb.

The molecular formula is C₂₉H₂₆ClFN₄O₄S with a molecular weight of 581.1 g/mol (CAS 231277-92-2). Reported solubility is approximately 0.33 mg/mL in 1:2 DMSO:PBS (pH 7.2) and approximately 20 mg/mL in DMSO. The product is stable at -20°C for 12 months from date of receipt, should be protected from prolonged exposure to light, and is intended for research use only.

Published cancer research applications include induction of apoptosis in cells overexpressing EGFR and/or HER2 and inhibition of tumor growth in a mouse xenograft model. According to the Safety Data Sheet, the substance is not classified as hazardous under GHS, though ingestion may cause diarrhea, nausea, abdominal cramping, rash, and fatigue, and the use of personal protective equipment such as chemical-resistant gloves, a lab coat, and safety glasses is recommended during handling.